– October 1, 2009
October 1, 2009
View Issues
-
Sunitinib and Cardiovascular Toxicity
In a retrospective review of 175 sunitinib-treated renal cell carcinoma patients, grade 3 hypertension was observed in approximately 10% and grade 3 left ventricular dysfunction and/or congestive heart failure in 7%. -
XP For Metastatic HCC
Successful treatment for patients with metastatic HCC remains elusive. In this Phase II study, a combination of capecitabine and cisplatin was administered safely to a cohort of 32 HCC patients with measurable extrahepatic disease. -
Severe Leukocytosis in Solid Tumor Patients
Very limited data exist regarding causes and prognosis for extreme leukocytosis among non-hematologic malignancy patients. -
Dasatinib for Imatinib- resistant CML: Two Years Later
In a two-year follow-up of an initial report of a multisite, randomized trial comparing dasatinib 70 mg twice daily with imatinib 400 mg twice daily for patients who had proven resistant to lower doses of imatinib (400 mg or 600 mg daily), the improved cytogenetic responses initially reported appear durable, and the estimated progression-free survival was better for the dasatinib-treated patients. -
Bisphosphonates and Overall Survival for Prostate Cancer Patients
In a late analysis of two trials conducted to test whether an oral bisphosphonate would influence outcomes in patients with prostate cancer, it is apparent that for those with metastatic disease, treatment resulted in improved overall survival. However, for those patients who did not have metastatic disease, bisphosphonate treatment had no effect on overall survival. -
Clinical Briefs in Primary Care Supplement
-
Pharmacology Watch
WHO recommendations for antiviral use for H1N1 flu; antibiotic use trends for acute respiratory tract infection; denosumab clears FDA Expert Panel; FDA Actions.